The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISHL HL Update 2021 | Personalized approaches to Hodgkin lymphoma
Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, touches on the importance of a personalized treatment approach in the management of Hodgkin lymphoma, as well as the identification of novel response biomarkers that can guide treatment strategies in this patient population. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.
